carboplatinepirubicincyclophosphamidepaclitaxelanthracyclinetriple negative breast cancer
…t related adverse events was 66.7% (269 of 403 patients) in the carboplatin arm and 55.0% (222 of 404 patients) in the control arm. No trea…
5articles mentioning drugs
7drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Epirubicin ×
Epirubicin
This drug is selected. Its supporting articles are shown below.
Articles mentioning Epirubicin
5 articles · page 1 of 1pembrolizumabcarboplatinpaclitaxelepirubicincyclophosphamiderituximabtriple-negative breast carcinoma (TNBC)neoadjuvant chemo-immunotherapy
…ocol (paclitaxel, carboplatin, epirubicin, cyclophosphamide and pembrolizumab). Following the sixth cycle, she developed refractory focal sei…
158 The cellular basis of anthracycline-induced cardiotoxicity; role and sources of oxidative stress
DoxorubicindaunorubicinidarubicinepirubicinAnthracyclinesfebuxostatN-Acetyl CysteineVAS2870childhood cancer
… for photometric measurement of intracellular oxidative stress. Doxorubicin, daunorubicin, idarubicin and epirubicin increased intracellula…
paclitaxelEpirubicinepirubicin-cyclophosphamidePbreast cancertertiary hospital
…eekly P due to intolerance and eleven patients did not complete paclitaxel: four due to severe infusional reaction, two due to myelotoxici…
docetaxelcarboplatinTrastuzumab deruxtecantrastuzumab emtansineribociclibletrozolepaclitaxeltrastuzumabT-DXdpertuzumab+7 more
…erapy will be included and randomised 1:1 to receive either (1) docetaxel (or paclitaxel), carboplatin, trastuzumab (H) and pertuzumab (P…